Giddy-up: Novartis Weighs “White Knight” Options In Sanofi Bid For Aventis
This article was originally published in The Tan Sheet
Executive Summary
A Novartis-Aventis combination would give the Franco-German firm a substantial consumer healthcare division to support the OTC sale of the allergy drug Allegra (fexofenadine) were Aventis to switch the drug from Rx status
You may also be interested in...
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company